Neuraxis, INC (NRXS) — 10-Q Filings

All 10-Q filings from Neuraxis, INC. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Neuraxis Sales Surge 35% Amid Rising Losses, Strategic License Recapture — Nov 10, 2025 Risk: high
Neuraxis, Inc. (NRXS) reported a net loss of $2,122,796 for the three months ended September 30, 2025, an increase from a net loss of $1,755,234 in the prior ye
Neuraxis Narrows Losses Amid Strong Revenue Growth, Recaptures Key IP — Aug 12, 2025 Risk: medium
Neuraxis, Inc. (NRXS) reported a net loss of $1,690,418 for the three months ended June 30, 2025, a significant improvement from the $2,917,710 net loss in the
Neuraxis, Inc. Files Q1 2025 10-Q — May 12, 2025 Risk: low
Neuraxis, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, including balance sh
Neuraxis, Inc. Files Q3 2024 10-Q Report — Nov 12, 2024 Risk: medium
Neuraxis, Inc. filed its 10-Q for the period ending September 30, 2024. The company, located in Carmel, Indiana, operates in the electromedical and electrothera
Neuraxis, Inc. Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
Neuraxis, Inc. filed its 10-Q for the period ending June 30, 2024. The company, located in Carmel, Indiana, operates in the electromedical and electrotherapeuti
Neuraxis, Inc. Files Q1 2024 10-Q Report — May 20, 2024 Risk: low
Neuraxis, Inc. filed its 10-Q for the period ending March 31, 2024. The filing details financial information and business operations for the first quarter of 20

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX